|
|
Dbv Technologies S a (NASDAQ: DBVT) |
|
Price: $4.4000
$-0.34 
-7.173%
|
| Day's High:
| $4.5962
| Week Perf:
| -6.98 %
|
| Day's Low: |
$ 4.38 |
30 Day Perf: |
44.26 % |
| Volume (M): |
18 |
52 Wk High: |
$ 6.63 |
| Volume (M$): |
$ 79 |
52 Wk Avg: |
$4.54 |
| Open: |
$4.47 |
52 Wk Low: |
$2.52 |
|
|
| Market Capitalization (Millions $) |
71 |
| Shares
Outstanding (Millions) |
16 |
| Employees |
95 |
| Revenues (TTM) (Millions $) |
13 |
| Net Income (TTM) (Millions $) |
-102 |
| Cash Flow (TTM) (Millions $) |
-103 |
| Capital Exp. (TTM) (Millions $) |
3 |
Dbv Technologies S A
Dbv Technologies S.A. is a biopharmaceutical company that specializes in developing immunotherapy treatments for various allergic diseases. The company is based in France and was founded in 2002.
Dbv Technologies is known for its innovative approach to treating allergies, particularly through its Viaskin' platform. This platform utilizes epicutaneous immunotherapy (EPIT) to deliver allergens to patients through a patch worn on the skin. By gradually exposing the immune system to small doses of allergens, the company aims to desensitize patients and reduce allergic responses.
The company's lead product, Viaskin Peanut, is currently under development for the treatment of peanut allergies, which is a common and potentially life-threatening allergy. Dbv Technologies has conducted clinical trials to assess the efficacy and safety of Viaskin Peanut, and the results have been promising. If approved, Viaskin Peanut could become a significant breakthrough in the treatment of peanut allergies.
Dbv Technologies is also investigating potential applications of its Viaskin platform for other allergens, including milk, eggs, and other food allergies. The company has ongoing research and development efforts to expand its product portfolio and address unmet medical needs in the field of allergies.
In summary, Dbv Technologies S.A. is a biopharmaceutical company focused on developing immunotherapy treatments for allergies. Through its Viaskin platform, the company aims to revolutionize the treatment options for patients suffering from allergic diseases, potentially improving their quality of life.
Company Address: 107 Av. de la République Châtillon 92320
Company Phone Number: 1 55 42 78 78 Stock Exchange / Ticker: NASDAQ DBVT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dbv Technologies S A
Dbv Technologies Reports Wider Losses and Declining Revenue: What It Means for Investors
Location: - Dbv Technologies S A has reported disappointing financial results for the period from April to June 30, 2024, raising concerns among investors and stakeholders about the company?s performance trajectory. The biotech firm, known for its innovative approaches to allergy treatments, posted a net shortfall of $33.116 million, a significant increase from $24.243 million in the same quarter a year earlier.
The company?s loss per share also widened to $-0.34, compared to $-0.26 in the corresponding period last year, and a decline from $-0.28 in the previous quarter. This continuous increase in losses reflects pressing challenges that are prompting reconsideration of the company's operational strategies.
Revenue for the quarter was particularly stark, declining by 49.257% to $1.16 million?down from $2.29 million over the same period last year. Sequentially, revenue also fell 17.484% from $1.41 million in the prior quarter. Such severe revenue contraction raises serious questions about the firm?s market position and competitiveness, as it struggles to gain traction in an evolving biotech landscape.
|
| Dbv Technologies S A
DBV Technologies S.A. experienced a challenging first quarter of 2024 earnings season, with an increase in the shortfall per share compared to the previous year and the previous quarter. The company reported a shortfall per share of $-0.28, which was higher than the $-0.22 reported a year ago and the $-0.11 reported in the prior quarter. This indicates that the company's financial performance worsened during this period.
The decline in earnings was accompanied by a decrease in revenue. DBV Technologies S.A. reported a revenue of $1.41 million in the first quarter of 2024, which was a significant decrease of -35.871% compared to the $2.19 million reported in the same quarter a year ago. Sequentially, the revenue tumbled even further, declining by -84.145% from $8.87 million in the previous quarter. This decline in revenue suggests that the company faced challenges in generating sales during this period.
|
| Dbv Technologies S A
DBV Technologies, a biotechnology and pharmaceutical company, recently released its financial results for the October to December 31, 2023 interval. The figures reveal a combination of positive and negative trends that question the company's potential trajectory. This article aims to interpret these results and evaluate their possible impact on DBV Technologies going forward.
Revenue Growth and Decreasing Deficit:
DBV Technologies reported a significant increase in revenue, reaching $8.874 million in the October to December 2023 interval, representing a 224.69% growth compared to the previous year's revenue of $4.84 million. This growth demonstrates the company's ability to generate more income, possibly due to successful product launches, increased market demand, or expanded partnerships.
|
| Dbv Technologies S A
/>DBV Technologies S.A., a leading player in the biotechnology and pharmaceuticals industry, has recently released its financial results for the July to September 2023 financial period. A closer look at the numbers reveals several positive trends and achievements, despite some challenges that the company faced during this period.
Positive Earnings and Revenue Growth:
One of the highlights of DBV Technologies' financial results is the decrease in loss per share compared to the previous year. The company managed to reduce its loss per share from $-0.18 to $-0.17, indicating progress in managing its costs and improving its financial position. Furthermore, the income per share increased from $-0.26 to $-0.17, indicating a positive shift in DBV Technologies' ability to generate income.
|
| Dbv Technologies S A
Investors in the stock market are always on the lookout for promising opportunities, and one company that deserves attention is DBV Technologies S.A., a Biotechnology & Pharmaceuticals company. Despite facing challenges in the most recent fiscal period, DBV Technologies has shown incredible resilience and potential for growth.
In the previous fiscal period, DBV Technologies encountered a loss of $0.26 per share. However, the company's revenue witnessed an impressive surge of 49.64%, reaching $2.29 million compared to the previous year. This surge showcases DBV Technologies' ability to withstand the downward trend seen in the Biotechnology & Pharmaceuticals sector, which experienced a significant decline in revenues across the board.
|
| Per Share |
Current |
| Earnings (TTM) |
-6.32 $ |
| Revenues (TTM) |
0.78 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.9 $
|
| Book Value |
3.37 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-6.32 $
|
| Revenues (TTM) |
0.78 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.9 $
|
| Book Value |
3.37 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
